Shares in Carl Zeiss Meditec AG show a positive technical chart pattern over the medium term. The timing to jump back on the rising trend seems good. Investors have an opportunity to buy the stock and target the € 145.
The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
Thanks to a sound financial situation, the firm has significant leeway for investment.
The group usually releases upbeat results with huge surprise rates.
Sales forecast by analysts have been recently revised upwards.
For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
Within the weekly time frame the stock shows a bullish technical configuration above the support level at 106.7 EUR
Stock prices approach a strong long-term resistance in weekly data at EUR 138.3.
The stock is close to a major daily resistance at EUR 138.7, which should be gotten rid of so as to gain new appreciation potential.
Based on current prices, the company has particularly high valuation levels.
The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 63.89 times its estimated earnings per share for the ongoing year.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
Subsector Other Advanced Medical Equipment & Technology
Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.